Thomas N, Rajaratnam Simon, Shanthly Nylla, Oommen Regi, Seshadri M S
Department of Endocrinology, Christian Medical College, Vellore, Tamil Nadu, India.
J Assoc Physicians India. 2006 Jul;54:525-9.
Paget's disease is a localized disorder of the skeleton characterized by increased osteoclastic activity. While the prevalence in the Western Population is 1-2%, the prevalence in India is not known. We studied the clinical profile, biochemical parameters, bone scans, therapeutic details and follow up data of patients with Paget's disease, attending the Endocrinology outpatient clinic in our institution.
A retrospective review was done of the medical records of 51 patients seen in a tertiary referral centre in Southern India from 1995 to 2003. The data was analyzed using SPSS 9.0 software package.
There were a total of 51 patients (41 male and 10 female). The mean age at presentation was 56 years and the mean duration of symptoms was 43 months. At least 6 months of follow-up was available in 31 patients and longer term (>2 years) follow-up in 22 patients. The symptoms at presentation were bone pain in 65%, low backache in 37%, skeletal deformities in 33%, pathological fractures in 20%, neurogenic claudication in 4%, deafness and head enlargement in 7% and renal stones in 4% of subjects. Five patients (9.8%) were asymptomatic and were incidentally diagnosed during evaluation of an elevated alkaline phosphatase. The mean serum alkaline phosphatase (range and SD) at the time of presentation was 690 IU/L (91-3873 U/L, 698 U/L). There was no statistically significant difference in the serum alkaline phosphatase values between female and male patients (576 U/L versus 718 U/L). Polyostotic involvement was seen in 90.2% of the patients. The pattern of skeletal involvement was very similar to that described in the Western literature. Twenty patients were started on Calcitonin and of these, 13 patients were later changed over to bisphosphonates to induce remission. In all, thirty six subjects received Alendronate and of them, 31 received lower doses (10-20mg/day). All the treated patients showed a good clinical and biochemical improvement. Two patients with severe Pagetic involvement of the bone who also had neurologic symptoms (root pains in one and cauda equina lesion in the other) needed intravenous Pamidronate to obtain a rapid response in the initial phase of treatment.
In our series, Paget's disease had a male predominance. The clinical presentation and the pattern of skeletal involvement was similar to the Western series. Serum alkaline phosphatase declined by 40% at 6 months of therapy and by 64% by one year of treatment in patients who were on lower doses of Alendronate (10-20 mg/day) in our series, which is similar to what has been described with conventional doses (40 mg per day) in the Western series.
佩吉特病是一种以破骨细胞活性增加为特征的局限性骨骼疾病。西方人群中的患病率为1%-2%,而印度的患病率尚不清楚。我们研究了在我们机构内分泌门诊就诊的佩吉特病患者的临床特征、生化参数、骨扫描、治疗细节及随访数据。
对1995年至2003年在印度南部一家三级转诊中心就诊的51例患者的病历进行回顾性分析。使用SPSS 9.0软件包对数据进行分析。
共有51例患者(41例男性,10例女性)。就诊时的平均年龄为56岁,症状的平均持续时间为43个月。31例患者至少有6个月的随访数据,22例患者有长期(>2年)随访数据。就诊时的症状包括:65%的患者有骨痛,37%的患者有腰痛,33%的患者有骨骼畸形,20%的患者有病理性骨折,4%的患者有神经源性间歇性跛行,7%的患者有耳聋和头颅增大,4%的患者有肾结石。5例患者(9.8%)无症状,在碱性磷酸酶升高的评估过程中被偶然诊断。就诊时血清碱性磷酸酶的平均值(范围和标准差)为690 IU/L(91-3873 U/L,698 U/L)。女性和男性患者的血清碱性磷酸酶值无统计学显著差异(576 U/L对718 U/L)。90.2%的患者有多骨受累。骨骼受累模式与西方文献中描述的非常相似。20例患者开始使用降钙素治疗,其中13例患者后来改用双膦酸盐以诱导病情缓解。总共有36例患者接受了阿仑膦酸钠治疗,其中31例接受较低剂量(10-20mg/天)。所有接受治疗的患者在临床和生化方面均有良好改善。2例骨骼严重受累且伴有神经症状(1例为神经根痛,另1例为马尾神经病变)的患者在治疗初期需要静脉注射帕米膦酸钠以获得快速反应。
在我们的研究系列中,佩吉特病以男性为主。临床表现和骨骼受累模式与西方研究系列相似。在我们的研究系列中,接受较低剂量阿仑膦酸钠(10-20mg/天)治疗的患者在治疗6个月时血清碱性磷酸酶下降40%,治疗1年时下降64%,这与西方研究系列中使用常规剂量(40mg/天)时所描述的情况相似。